Clinical Research
corporate_fare

Splicebio S.L.

Address
Carrer De Baldiri Reixac 10-12, Poligono Industrial Parc Cientific De Barcelona

Sponsor Overview

assignment
1
sponsored trial
science
2
molecules
location_city
3
research centres
public
2
countries
person_search
3
investigators

Specializations

Inherited Retinal Disease

Splicebio S.L. focuses on Stargardt disease, with particular interest in Stargardt disease type 1 linked to ABCA4 gene mutations and the resulting retinal degeneration seen in inherited macular disorders.

  • Stargardt disease
  • Stargardt disease type 1
  • ABCA4 mutation-associated retinal disease

The sponsor’s clinical activity is directed toward ophthalmic conditions affecting central vision and retinal structure.

Gene-Linked Ophthalmology

Its research interest includes genetically confirmed retinal disease, with emphasis on patients carrying biallelic ABCA4 mutations and the therapeutic implications of correcting disease driven by a defined molecular defect.

  • Genotype-confirmed retinal disorders
  • Biallelic ABCA4 mutations
  • Molecularly targeted eye disease

This places the sponsor within the field of precision-oriented ophthalmic genetics.

Retinal Gene Therapy

Splicebio S.L. is engaged in retinal gene therapy centered on subretinal administration for a degenerative retinal condition, reflecting therapeutic interest in restoring retinal function through localized ocular intervention.

  • Subretinal delivery
  • Ocular gene-based treatment
  • Retinal function preservation

The sponsor’s program is aligned with treatment strategies for macular degeneration driven by inherited disease mechanisms.

Ophthalmic Safety and Tolerability

Its clinical research also addresses safety, tolerability, and early efficacy assessment in an ocular setting, supporting development in diseases where visual impairment is progressive and treatment options remain limited.

  • Ocular safety
  • Tolerability assessment
  • Preliminary efficacy in retinal disease

These interests are concentrated in vision-threatening inherited retinal disorders.

Sponsored Trials

Trial Name Country Status
Evaluation of Safety, Tolerability, and Preliminary Efficacy of Subretinal SB-007 Injection in Stargardt Disease with Bi-Allelic ABCA4 MutationsBelgium BelgiumGermany GermanyRecruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
2
Exclusive Molecules
out of 2 total (100% not shared with other sponsors)

This sponsor works with 2 molecules, of which 2 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
0%
Return partnership rate
0 of 3 sites collaborated multiple times

This sponsor has worked with 3 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Eye Diseases1 trial
    138 other sponsors

Partnered Research Centres

3 centres
location_city
assignment383
Rheinische Friedrich-Wilhelms-Universitaet Bonn
Address
Venusberg-Campus 1, Venusberg, 53127 Bonn
Learn morearrow_forward
location_city
assignment628
Universitaetsklinikum Tuebingen AöR
Address
Otfried-Mueller-Strasse 10, Nordstadt, 72076 Tübingen
Learn morearrow_forward
location_city
assignment811
Universitair Ziekenhuis Gent
Address
Corneel Heymanslaan 10, 9000 Ghent
Learn morearrow_forward

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Splicebio S.L..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.